Latanoprost Teva-Ratiopharm

Latanoprost, the active ingredient in Latanoprost Teva‑Ratiopharm, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to treat primary open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost Teva‑Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable supply chain management across global markets.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers intra‑ocular pressure to prevent development of glaucoma. Elevated intra‑ocular pressure (general): helps to decrease pressure regardless of underlying diagnosis.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and thickness. - Darkening of iris color. - Eye irritation or foreign‑body sensation. - Blurred vision. - Mild eye pain.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema). - Uveitis or intra‑ocular inflammation. - Corneal edema or keratitis. - Macular edema leading to visual disturbance. - Sudden loss of vision. - Persistent intra‑ocular pressure spikes.

Before using Latanoprost, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefits outweigh risks. Breastfeeding: unknown; use with caution. Active ocular infection: contraindicated until infection resolves. Intra‑ocular pressure monitoring: assess pressure after initiation and periodically thereafter. Concurrent prostaglandin analogs: avoid to reduce risk of additive ocular effects. Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops may increase risk of ocular side effects. - Use with non‑steroidal anti‑inflammatory eye drops may diminish efficacy. - Systemic carbonic anhydrase inhibitors may produce additive intra‑ocular pressure reduction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops may have additive IOP‑lowering effect; monitor pressure. - Alpha‑agonist eye drops may enhance pressure reduction; observe response. - Systemic antihypertensive agents generally have minimal interaction but should be reviewed.